Will Houlihan Lokey (HLI) Beat Estimates Again in Its Next Earnings Report?

Houlihan Lokey (HLI), an investment banking firm in the Zacks Financial - Miscellaneous Services industry, has a strong recent earnings surprise record with an average surprise of 17.75% over the past two quarters (most recent: $1.84 EPS vs $1.69 estimate, +8.88%; prior quarter: $2.14 vs $1.69, +26.63%). Analysts have become marginally more bullish ahead of the next release — Zacks reports an Earnings ESP of +2.19% and a Zacks Rank #3 (Hold), a combination that historically correlates with a roughly 70% chance of an earnings beat; the next report is expected Jan. 28, 2026. Investors should note the positive revision momentum and beat history as potential catalysts, but the coverage is advisory in nature and not a guarantee of future outperformance.

Analysis

Market structure: Houlihan Lokey (HLI) benefits directly from sustained M&A and restructuring activity; two-quarter average EPS surprise of 17.75% and an Earnings ESP of +2.19% suggest above-consensus fees and deal closings concentrated in the near term (next 1–3 quarters). Competitors (boutique advisory firms, lower-tier IB desks) risk losing market share if HLI’s advisory pipeline accelerates; conversely, market infrastructure players (NDAQ) and commoditized brokers gain less from a spike in closed deals. On supply/demand, rising deal flow tightens supply of sell-side advisory capacity, which can lift margins 200–400 bps seasonally in HLI-like boutiques.

Risk assessment: Tail risks include a macro freeze in M&A (credit spread widening >150bp) or a large deal break that could swing quarterly revenue ±20–30% — such events could erase a beat. Immediate risk (days) is IV re-pricing into the Jan 28, 2026 print; short-term (weeks) hinges on post-earnings commentary about pipeline; long-term (quarters) depends on sustained capital markets activity and regulatory changes to transaction fees. Hidden dependencies: revenue timing (deal closings) and contingent fees create lumpy quarters; FX is minor but credit market health is a key second-order effect.

Trade implications: Direct play is tactical long HLI into earnings with defined-risk options rather than shares to avoid IV crush on a miss. Relative-value: long HLI vs short/underweight NDAQ or XLF exposure for 1–3 month horizon to isolate advisory upside versus market infrastructure. If conviction is moderate, use call spreads to limit premium; if directional and longer-term (3–12 months), consider buying shares with 6–12% position sizing and hedging with OTM puts.

Contrarian angles: Consensus may over-index to near-term EPS beats and underweight a potential pullback if M&A reverses; a beat does not guarantee >10% stock move given IV already prices some upside. Historical parallels (cyclical advisory firms in 2014–15 and 2020) show sustained outperformance requires multi-quarter deal flow; absent that, mean reversion can be swift. Unintended consequence: crowding into HLI before earnings could steepen IV and make any miss disproportionately punitive to shareholders and short-dated call buyers.

Key Decisions for Investors

• Establish a tactical 2–3% long position in HLI using a Jan 29, 2026 1-week call spread (buy ATM call, sell +10% strike) sized so max loss = 0.5% portfolio; target 15–30% upside on the spread or exit if HLI moves down >8% pre-earnings.
• If seeking longer exposure, initiate a 3–4% buy in HLI shares post-earnings (avoid buying into IV spike). Hedge with 3–6 month 10% OTM puts sized 50% of notional to cap drawdown if guidance disappoints.
• Execute a pair trade: go long HLI (1–2% allocation) and short NDAQ (1% allocation) for 1–3 months to capture advisory-specific upside; tighten stop-loss if HLI/NDAQ ratio falls below its 30-day SMA by >3%.
• If earnings IV is >annual average by >20%, sell a portion of expected premium by writing 1–2 month covered calls on newly acquired HLI shares (strike ~+8–12%) to monetize elevated volatility while retaining upside up to the strike.